According to meta-analysis of 13 papers’ outcomes, findings revealed a substantial specificity for the measurement of serum-HER2 in breast cancer diagnosis (Specificity: 79.27, 95%CI 73.02–85.51). This evidence concerns the gene ERBB2 and breast carcinoma.